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Standardize or Personalize?*Martine Gilard, MD, PHD,y Marie Claude Morice, MDzSEE PAGE 2211T he duration of dual antiplatelet therapy isthe subject of debate. Prolonged dual anti-platelet therapy may prevent recurrence of
thrombotic events, such as stroke or myocardial
infarction (MI), caused by either iterative plaque
rupture or complications related to previous revascu-
larization, with increased risk of bleeding. Multiple
factors have to be integrated: type of stent, clinical
presentation, type of dual antiplatelet therapy, coro-
nary lesion complexity, and patient compliance.
The current European guidelines (1) recommend 6
months’ dual antiplatelet therapy in stable patients
with coronary artery disease undergoing elective
percutaneous coronary intervention with second-
generation drug-eluting stents, and 12 months in pa-
tients with acute coronary syndrome, unless there
are contraindications, such as excessive risk of
bleeding. Thereafter, patients should be switched to
single antiplatelet therapy.
Seven randomized studies (2–8), comprising 15,378
patients, compared short versus long durations of
dual antiplatelet therapy, consisting of aspirin and
clopidogrel. Data suggested no difference in various
combined clinical endpoints, and notably in ischemic
risk; higher rates of bleeding were reported with long-
duration dual antiplatelet therapy, although not in all
studies.
The effect of longer treatment is not clear. Concern
exists regarding the balance between reducing
thrombotic events and increasing the risk of bleeding
complications, associated with adverse outcome.*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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this paper to disclose.Two recent double-blind randomized trials, Dual
Antiplatelet Therapy (DAPT) (n ¼ 9,961) and
PEGASSUS-TIMI 54 (n ¼ 21,162) (9,10), analyzed the
effect of dual antiplatelet therapy in terms of sec-
ondary prevention in stable patients. The results
suggest that long-duration dual antiplatelet therapy
signiﬁcantly reduced the rate of ischemic events
as compared with placebo combined with aspirin,
with an increase in moderate to severe bleeding.
Mauri et al. (9) found excess mortality associated with
clopidogrel or prasugrel, driven exclusively by an
increase in noncardiovascular mortality. The pop-
ulations of these 2 trials were different, with a higher
burden of risk factors in PEGASUS trial.In this issue of the Journal, Yeh et al. (11) present a
subanalysis of the DAPT study, according to patients’
clinical presentation (MI vs. non-MI), in which 9,961
patients who had completed 12 months’ dual anti-
platelet therapy after implantation of a drug-eluting
or bare-metal stent and free of major ischemic or
bleeding events were randomly assigned to an addi-
tional 18 months’ thienopyridine therapy (clopidogrel
or prasugrel) or placebo; all patients continued to
take aspirin. Continued dual antiplatelet therapy was
associated with signiﬁcant reduction in stent throm-
bosis and MI, but increased moderate to severe
bleeding and noncardiovascular death. The authors
examined whether the ischemic beneﬁts and bleeding
risks associated applied to both patient populations
with and without acute MI. Of 11,648 patients ran-
domized in the DAPT trial, 3,576 (30.7%) presented
with acute MI; 1,680 of the MI patients (47%) pre-
sented with initial ST-segment elevation MI and
the remainder with non–ST-segment elevation MI.
Because this variable was not factored in the
randomization, the characteristics of the 2 groups
differed: non-MI patients were older; more often
female; and showed higher rates of diabetes,
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2223peripheral disease, and prior percutaneous coronary
intervention. Patients with MI received a drug-eluting
stent in 72.4% of cases, compared with 91.3% of pa-
tients without MI, and had a higher rate of prasugrel
and less complex lesions. The authors found a
signiﬁcantly higher rate of deﬁnite or probable stent
thrombosis (1.2% vs. 0.7%; p ¼ 0.01) and recurrent MI
(3.7% vs. 2.8%; p ¼ 0.01), primarily related to stent
thrombosis, in MI patients. Bleeding (Gusto moderate
to severe and BARC 2 and 3) was less frequent in MI
patients. There was no difference in the rates of death
or stroke between the 2 groups. When Yeh et al. (11)
analyzed the treatment effect, continuing therapy
beyond 12 months was associated with signiﬁcant re-
ductions in stent thrombosis and MI rates in both
groups, but with greater magnitude in MI patients and
increased bleeding in both groups. In non-MI patients,
however, the authors reported signiﬁcantly increased
mortality (2.1% vs. 1.5%; hazard ratio: 1.43; 95% con-
ﬁdence interval: 1.02 to 2.00; p ¼ 0.04) and noncardiac
death with continued thienopyridine therapy in non-
MI patients (1.0% vs. 0.5%; hazard ratio: 2.26; 95%
conﬁdence interval: 1.3 to 3.94; p ¼ 0.002). However,
Yeh et al. (11) concluded that the effect of continued
treatment was comparable in both groups.
According to the investigators, this increase in
noncardiovascular mortality was not exclusively
caused by an increase in bleeding-related death.
A meta-analysis that they published in the Lancet,
including 14 trials (n ¼ 69,644) (12), reported that
treatment duration had no signiﬁcant effect on
mortality across studies. However, the selected
populations included might not be representative
of current practice in patients with stable coronary
artery disease. The trials included a mixture of
patients presenting with elective and acute coro-
nary syndromes, heterogeneity of stent type, a
wide range of short (3, 6, and 12 months) and
long (6, 12, 24, and 30 months) dual antiplatelet
therapy regimes, and various P2Y12 inhibitors. In the
recent meta-analysis by Palmerini et al. (13),
including 10 recent trials (n ¼ 31,666), all-cause
mortality also was signiﬁcantly lower for short-
duration dual antiplatelet therapy, because of a
33% lower rate of noncardiovascular mortalitydespite a signiﬁcantly lower rate of stent thrombosis
in long-duration dual antiplatelet therapy. The
PEGASUS trial, including only patients with previous
MI, reported no difference in mortality rates. In the
trial conducted by Yeh et al. (11), there was no
difference in mortality in MI patients according to
dual antiplatelet therapy duration. There is a possi-
bility that only high-risk patients beneﬁt from long-
duration dual antiplatelet therapy. We are not
convinced by the authors’ argument that the signif-
icant increase in noncardiac mortality observed in
the non-MI group could be incidental, and that
the trial can be considered positive in the long-
duration arm.
This requires further exploration before it can be
recommended that dual antiplatelet therapy should
be prolonged beyond 1 year. In the meantime, a
personalized approach, in which the individual
risk-beneﬁt proﬁle of each patient is carefully
considered, should be recommended, rather than a
1-size-ﬁts-all policy (Figure 1).
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